LSCs are known to be resistant to TKIs through BCR::ABL1-independent mechanisms [20], and so can persist after successful TKI-induced remission, acting as a reservoir for CML relapse. Here, ABL1 is linked to chronic myelogenous leukemia, BCR-ABL1 positive.